Redefining microbiome-based therapeutics

MRM Health's proprietary technology platform brings live microbial therapeutics development to the next level by combining rationally selected strains into synergistic consortia through a proprietary optimization process.

About MRM Health

MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome.

Microbiome experts

MRM Health is based in a Center of Expertise for microbiome research and development in the biotech cluster in Ghent and has a strategic partnership with the VIB, with top research groups in both microbiome analysis and ecology and in host biology and disease research.

Strong industrial and financial support

MRM Health has a corporate collaboration with DuPont Nutrition Biosciences in the discovery and development of microbiome-based therapeutics in the field of metabolic diseases. Other therapeutic areas are available for partnering. The Company is strategically supported by strong local and international investors, including Ackermans & van Haaren, DuPont, MRM Technologies, Qbic II and VIB.

Our discovery engine

MRM Health combines a number of proprietary innovative technologies as its discovery engine. This includes direct access to the most advanced simulator of the human gut, the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®). In addition, through strategic partnerships with international research centers, MRM Health has secured extensive complementary microbiome and bioinformatics capabilities and taps into a multidisciplinary knowhow in inflammatory diseases and patient insights.

Our Unique Technology

Patient-driven strain selection

Selection, isolation and functional characterization of strains based on unique clinical datasets and in-human discovery approaches, in combination with access to proprietary strain libraries.

Microbial Resource Management

Rational design and optimization into defined synergistic multi-strain bacterial consortia.

Proprietary optimization

Proprietary optimization process, resulting in oral formulation with improved viability, resilience, engraftment and functional responses and in superior efficacy in restoration of microbial metabolic networks and host-disease endpoints.

Find out more about our technology

Interested in working with us ?

Contact us now

Partnership with VIB, KU Leuven and UGent

VIB is an excellence-based entrepreneurial research institute in life sciences that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. VIB works in close partnership with Flemish universities, including KU Leuven and Ghent University.

Diversified pipeline

MRM Health's most advanced program is MH002, a drug candidate for Inflammatory Bowel Disease (IBD), which includes Ulcerative Colitis (UC) and Crohn's disease (CD). MH002 is an optimized consortium of bacteria, consisting of rationally selected and well-characterized commensal strains, resulting in a synergistic consortium with multiple disease-modifying potential.

Other ongoing discovery programs including Spondyloarthritis and Neurology as well as targeting other medical conditions with high unmet medical need.

MRM Health has a collaboration with DuPont Nutrition Biosciences in the discovery and development of microbiome-based therapeutics in the field of metabolic diseases. In addition to the drug candidates, MRM Health's pipeline includes two advanced single strain probiotics with differentiating Mode-of-Action and advanced development status for the medical nutrition / OTC and consumer markets (PD01 and PD12).

More Soon